MCID: LVR013
MIFTS: 69

Liver Disease

Categories: Blood diseases, Bone diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Liver Disease

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 12 15 37 17
Liver Diseases 54 42 44 71
Liver Failure 29 54 6 71
Abnormality of the Liver 29 6
Liver Dysfunction 54 71
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Disease 15

Classifications:



External Ids:

Disease Ontology 12 DOID:409
ICD9CM 34 573.9
MeSH 44 D008107
NCIt 50 C3196
SNOMED-CT 67 62857009
UMLS 71 C0023895 C0085605 C0086565

Summaries for Liver Disease

MedlinePlus : 42 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and non-alcoholic fatty liver disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Folate Metabolism and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Glimepiride and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone marrow, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 74 Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 3
Infantile Liver Failure Syndrome Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1883)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 33.9 SLC17A5 PNPLA3 INS GPT GGT1 ADIPOQ
2 non-alcoholic fatty liver disease 33.8 SERPINA1 PNPLA3 INS GPT GGT1 ALB
3 polycystic liver disease 33.7 SERPINA1 SEC63 PRKCSH PKHD1 PKD1 GGT1
4 non-alcoholic steatohepatitis 33.4 PNPLA3 INS GPT ALB ADIPOQ
5 polycystic liver disease 1 with or without kidney cysts 33.3 SEC63 PRKCSH PKHD1 PKD1
6 alcoholic hepatitis 33.2 SLC17A5 PNPLA3 GPT GGT1 F2 ALB
7 polycystic kidney disease 4 with or without polycystic liver disease 33.1 SEC63 PRKCSH PKHD1 PKD1 GANAB
8 polycystic kidney disease 1 with or without polycystic liver disease 32.9 SEC63 PRKCSH PKHD1 PKD1 GANAB
9 polycystic kidney disease 2 with or without polycystic liver disease 32.9 SEC63 PRKCSH PKHD1 PKD1
10 alpha-1-antitrypsin deficiency 32.9 SERPINA1 GPT F2 ALB AFP
11 primary biliary cholangitis 32.8 SLC17A5 GPT GGT1 F2 DLAT ALB
12 hepatic vascular disease 32.8 SERPINA1 PKHD1 INS GPT F2 ALB
13 alcohol use disorder 32.7 SLC17A5 GPT GGT1 ALB
14 hemochromatosis, type 1 32.7 SERPINA1 INS GPT ALB AFP
15 cholangitis, primary sclerosing 32.7 SERPINA1 GPT GGT1 F2 DLAT ALB
16 hepatic encephalopathy 32.6 SLC17A5 GPT F2 ALB
17 sclerosing cholangitis 32.6 GPT GGT1 F2 ALB ABCB11
18 acute liver failure 32.6 SLC17A5 GPT F2 ALB
19 portal hypertension 32.5 PNPLA3 PKHD1 INS GPT F2 ALB
20 viral hepatitis 32.5 SLC17A5 SERPINA1 PNPLA3 INS GPT GGT1
21 alcoholic liver cirrhosis 32.4 SLC17A5 PNPLA3 INS GPT F2 ALB
22 hepatorenal syndrome 32.4 GPT F2 ALB
23 cholestasis 32.4 SLC17A5 SERPINA1 HSD3B7 GPT GGT1 F2
24 hepatitis 32.3 SLC17A5 GPT GGT1 F2 AFP
25 cholangitis 32.3 GPT GGT1 F2 DLAT ALB ABCB11
26 hepatic coma 32.3 GPT F2 ALB AFP
27 autoimmune hepatitis 32.3 SLC17A5 GPT GGT1 F2 DLAT ALB
28 hepatitis b 32.2 SLC17A5 GPT GGT1 F2 ALB AFP
29 liver cirrhosis 32.2 SLC17A5 SERPINA1 PNPLA3 MEG3 INS GPT
30 tyrosinemia, type i 32.2 SERPINA1 FAH AFP
31 type 2 diabetes mellitus 32.2 SLC17A5 PNPLA3 INS GPT GGT1 F2
32 congenital hepatic fibrosis 32.2 PKHD1 PKD1
33 body mass index quantitative trait locus 11 32.0 PNPLA3 INS GPT GGT1 ALB ADIPOQ
34 hepatitis a 32.0 SERPINA1 GPT F2 ALB AFP
35 polycystic kidney disease 32.0 PRKCSH PKHD1 PKD1 INS GANAB ALB
36 esophageal varix 31.9 SERPINA1 PKHD1 INS GPT F2 ALB
37 biliary atresia 31.9 GPT GGT1 F2 ALB ABCB11
38 idiopathic edema 31.9 INS ADIPOQ
39 kidney disease 31.9 PKHD1 PKD1 INS GANAB ALB ADIPOQ
40 glucose intolerance 31.8 INS GPT ALB ADIPOQ
41 autosomal dominant polycystic kidney disease 31.8 SEC63 PRKCSH PKHD1 PKD1 INS GANAB
42 sleep apnea 31.8 INS GPT ALB ADIPOQ
43 hyperuricemia 31.7 INS GPT GGT1 ALB
44 hypothyroidism 31.7 INS GPT F2 ALB ADIPOQ
45 bilirubin metabolic disorder 31.7 SLC17A5 GPT GGT1 F2 ALB ABCB11
46 obstructive jaundice 31.7 SLC17A5 GPT GGT1 F2 ALB
47 hepatitis e 31.6 GPT F2 ALB
48 cholelithiasis 31.5 INS GPT ALB
49 lipoprotein quantitative trait locus 31.5 SERPINA1 INS GPT F2 ALB ADIPOQ
50 schistosomiasis 31.5 GPT F2 ALB

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, hepatosplenomegaly, dyspepsia, icterus, heartburn, gastrointestinal gas, digestive system symptom, liver tender, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ADIPOQ ALB F2 FAH GGT1 INS
2 homeostasis/metabolism MP:0005376 10.1 ABCB11 ADIPOQ AFP ALB F2 FAH
3 endocrine/exocrine gland MP:0005379 9.97 ADIPOQ AFP ALB F2 FAH GGT1
4 liver/biliary system MP:0005370 9.93 ABCB11 ADIPOQ AFP ALB FAH HSD3B7
5 mortality/aging MP:0010768 9.86 ABCB11 ADIPOQ AFP ALB DLAT F2
6 renal/urinary system MP:0005367 9.28 ADIPOQ ALB FAH GGT1 INS PKD1

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 738)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glimepiride Approved Phase 4 93479-97-1 3476
2
Ezetimibe Approved Phase 4 163222-33-1 150311
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Temocillin Approved, Investigational Phase 4 66148-78-5
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
8
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
9
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
10
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
11
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
12
Promethazine Approved, Investigational Phase 4 60-87-7 4927
13
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Simeprevir Approved Phase 4 923604-59-5 66576988
16
Pantoprazole Approved Phase 4 102625-70-7 4679
17
Methocarbamol Approved, Vet_approved Phase 4 532-03-6 4107
18
Ibuprofen Approved Phase 4 15687-27-1 3672
19
Remifentanil Approved Phase 4 132875-61-7 60815
20
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
21
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
22
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
23
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
24
Liraglutide Approved Phase 4 204656-20-2 44147092
25
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
26
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
27
Desflurane Approved Phase 4 57041-67-5 42113
28
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
29
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31
Rifampicin Approved Phase 4 13292-46-1 5458213 5381226
32
Insulin detemir Approved Phase 4 169148-63-4 5311023
33
Insulin aspart Approved Phase 4 116094-23-6 16132418
34 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
35
Ethanolamine oleate Approved Phase 4 2272-11-9
36
Gliclazide Approved Phase 4 21187-98-4 3475
37
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
38
Montelukast Approved Phase 4 158966-92-8 5281040
39
Pravastatin Approved Phase 4 81093-37-0 54687
40
Haloperidol Approved Phase 4 52-86-8 3559
41
Nevirapine Approved Phase 4 129618-40-2 4463
42
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
43
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
44
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
45
Phentermine Approved, Illicit Phase 4 122-09-8 4771
46
Deferiprone Approved Phase 4 30652-11-0 2972
47
Methadone Approved Phase 4 76-99-3 4095
48
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
49
Lactulose Approved Phase 4 4618-18-2 11333
50
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 2194)
# Name Status NCT ID Phase Drugs
1 Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study Unknown status NCT02331745 Phase 4 Granulocyte colony-stimulating factor;standard treatment
2 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
3 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
4 The Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
5 Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients Unknown status NCT02882113 Phase 4 Advagraf
6 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme, a Randomised Controlled Trial Unknown status NCT01429779 Phase 4 Movicol
7 Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease. Unknown status NCT03063866 Phase 4 Propofol;Midazolam;Fentanyl
8 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
9 Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Unknown status NCT02649465 Phase 4 Tofogliflozin;Glimepiride
10 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
11 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
12 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
13 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
14 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients Unknown status NCT02051842 Phase 4 Metadoxine
15 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
16 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
17 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
18 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
19 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
20 Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Unknown status NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
21 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Unknown status NCT02764671 Phase 4
22 A Study Comparing Thymoglobulin to Tacrolimus in Liver Transplant and Impact on Renal Function Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
23 Temocillin Pharmacokinetics in Paediatrics Unknown status NCT02260102 Phase 4 Temocillin
24 A Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10 mg (Mitiglinide) in Type 2 Diabetes Mellitus Patients With Normal or Moderate Impaired Hepatic Function Completed NCT04349696 Phase 4 Mitiglinide
25 A Single-arm Evaluation of the Safety of Paliperidone Extended-Release (ER) in Subjects With Schizophrenia or Schizoaffective Disorder With Hepatic Disease Completed NCT00535145 Phase 4 Treatment as usual (TAU), Paliperidone ER
26 A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus Completed NCT01327547 Phase 4 Maraviroc;Placebo
27 Tenofovir Reduces Morbidity and Mortality in Patients With Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-chronic Liver Failure (ACLF): A Randomized Placebo Controlled Trial Completed NCT01074645 Phase 4 Tenofovir disoproxil fumarate (TDF)
28 Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients With Graves' Orbitopathy Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
29 Feasibility Study to Prevent Post-ICU Depression Completed NCT00872027 Phase 4 Escitalopram;Placebo
30 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease Completed NCT02366845 Phase 4
31 Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs Completed NCT03133065 Phase 4 treatment of HCV with oral direct acting antiviral therapy
32 Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients Completed NCT02432456 Phase 4 Ketamine;Placebo;Acetaminophen;Ibuprofen;Pantoprazole;Methocarbamol;Opioid
33 Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Completed NCT01501162 Phase 4 hepatitis, alcohol, probiotics;alcohol, hepatitis, Placebo
34 Prevention for Surgical Site Infection After Hepatic Resection Completed NCT00659698 Phase 4
35 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Completed NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
36 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Completed NCT01968395 Phase 4 Caspofungin 70 mg
37 The Effects of Purified n-3 Fatty Acids on Serum Fibrosis Markers and Cardiovascular Risk Markers in a Randomized Placebo Controlled Trial in Patients With Non Alcoholic Fatty Liver Disease Completed NCT00760513 Phase 4 OMACOR;Placebo oral capsule
38 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
39 An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C Completed NCT00163657 Phase 4 Daclizumub;Tacrolimus;Cyclosporine;MMF
40 Multicenter, Randomized, Open-label Clinical Trial to Compare Anidulafungin Versus Amphotericin B Safety in High Risk Hepatic Transplant Recipients Completed NCT01303549 Phase 4 Anidulafungin;Liposomal amphotericin B
41 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
42 Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation Completed NCT00402402 Phase 4
43 CellCept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients With Long-term Follow-up Post-transplantation for Non-Autoimmune Liver Disease - A Prospective, Randomized, Multicenter Trial. Completed NCT00206076 Phase 4 mycophenolate mofetil;mycophenolate mofetil
44 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
45 A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation Completed NCT02504138 Phase 4 Desflurane balanced anesthesia;Propofol total intravenous anesthesia
46 Preoperative Oral Supplementation of Carbohydrate and Branched-Chain Amino Acids-Enriched Nutrient Improves Insulin Resistance in Patients With Hepatectomy; Prospective Randomized Clinical Trial by Using Artificial Pancreas Completed NCT00657124 Phase 4
47 Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study Completed NCT02414880 Phase 4 Sugammadex;Neostigmine;Rocuronium
48 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Completed NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
49 A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease Completed NCT02347319 Phase 4 Pennel;Legalon;Placebo
50 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


alglucerase
imiglucerase
Medium chain triglycerides

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Liver Failure 29
2 Abnormality of the Liver 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

40
Liver, Kidney, Bone Marrow, Endothelial, Spleen, Bone, T Cells

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 49669)
# Title Authors PMID Year
1
Complementary and alternative therapies for non-alcoholic fatty liver disease: A Bayesian network meta-analysis protocol. 42 61
33530243 2021
2
Ursodeoxycholic acid improves pregnancy outcome in patients with intrahepatic cholestasis during pregnancy: A protocol for systematic review and meta-analysis. 42
33530164 2021
3
The impact of coronavirus disease 2019 (COVID-19) on liver injury in China: A systematic review and meta-analysis. 42
33530232 2021
4
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. 61 54
20371660 2010
5
Elevated hydroxyacylcarnitines in a carrier of LCHAD deficiency during acute liver disease of pregnancy - a common feature of the pregnancy complication? 61 54
20363656 2010
6
The PXR is a drug target for chronic inflammatory liver disease. 54 61
20416375 2010
7
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. 54 61
20503453 2010
8
The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. 61 54
20415685 2010
9
Beneficial effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver disease in high-fat fed C57BL/6 mice. 61 54
20490434 2010
10
Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy. 54 61
19942238 2010
11
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. 54 61
20200515 2010
12
Is alanine aminotransferase level a surrogate biomarker of hepatic apoptosis in nonalcoholic fatty liver disease? 54 61
20406065 2010
13
Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. 61 54
19881359 2010
14
Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. 54 61
19946731 2010
15
Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. 54 61
20473736 2010
16
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. 61 54
19931264 2010
17
Natural anticoagulants can be useful predictors of severity in chronic liver disease. 54 61
20019598 2010
18
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. 61 54
20335584 2010
19
The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. 61 54
20093562 2010
20
Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. 61 54
20150538 2010
21
Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. 61 54
19770674 2010
22
A novel c.592-4_c.592-3delTT mutation in DGUOK gene causes exon skipping. 54 61
19900589 2010
23
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. 54 61
19839004 2010
24
Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. 54 61
19829123 2010
25
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. 54 61
20176643 2010
26
Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. 61 54
19817962 2010
27
[The roles of cyclooxygenase-2 and 5-lipoxygenase in liver disease]. 61 54
20196963 2010
28
Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 54 61
20170533 2010
29
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. 54 61
19330428 2010
30
Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. 54 61
19910932 2010
31
Plasma interleukin-18/interleukin-18 binding protein ratio in Chinese with NAFLD. 61 54
20422882 2010
32
Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. 61 54
20043871 2010
33
The role of cytokines in non-alcoholic fatty liver disease. 54 61
20460908 2010
34
Animal models for hepatitis C and related liver disease. 61 54
20156300 2010
35
The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. 61 54
19940802 2010
36
Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. 61 54
19793164 2010
37
Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. 54 61
19950230 2010
38
Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. 54 61
19687773 2009
39
Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. 61 54
19769633 2009
40
[Fatty liver disease, insulin resistance and adiponectin in an obese pediatric population]. 61 54
19850541 2009
41
Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. 61 54
19948621 2009
42
Xenobiotic-sensing nuclear receptors CAR and PXR as drug targets in cholestatic liver disease. 61 54
19925451 2009
43
The unfolding clinical spectrum of POLG mutations. 61 54
19578034 2009
44
Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. 61 54
19278843 2009
45
Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. 61 54
19525859 2009
46
[Insulin resistance and islet beta cell function in type 2 diabetes mellitus and non alcoholic fatty liver disease.]. 61 54
20079327 2009
47
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. 61 54
19474742 2009
48
Chronically inflamed livers up-regulate expression of inhibitory B7 family members. 54 61
19739236 2009
49
Hemodynamic effects of albumin dialysis in patients with liver failure: for better or for worse? 61 54
19788454 2009
50
Increase of octanoate concentrations during extracorporeal albumin dialysis treatments. 54 61
19788462 2009

Variations for Liver Disease

ClinVar genetic disease variations for Liver Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYOM1 NM_003803.4(MYOM1):c.3260G>A (p.Trp1087Ter) SNV Likely pathogenic 804425 rs374670754 18:3116372-3116372 18:3116374-3116374
2 YARS1 NM_003680.3:c.611A>C SNV Uncertain significance 986742 1:33256836-33256836 1:32791235-32791235

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease

Pathways related to Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.79 INS GGT1 F2 ALB
2 11.38 SERPINA1 INS ALB AFP
3 10.57 INS F2 ALB AFP
4 10.46 INS GPT

GO Terms for Liver Disease

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 SERPINA1 PKHD1 PKD1 GPT GGT1 GANAB
2 extracellular space GO:0005615 9.92 SERPINA1 INS GPT GGT1 F2 ALB
3 endoplasmic reticulum GO:0005783 9.61 SERPINA1 SEC63 PRKCSH PKHD1 PKD1 HSD3B7
4 endoplasmic reticulum lumen GO:0005788 9.17 SERPINA1 PRKCSH INS GANAB F2 ALB
5 glucosidase II complex GO:0017177 9.16 PRKCSH GANAB

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to insulin stimulus GO:0032869 9.58 PNPLA3 GPT ADIPOQ
2 liver development GO:0001889 9.54 SEC63 PRKCSH PKD1
3 glucose metabolic process GO:0006006 9.5 INS DLAT ADIPOQ
4 acute-phase response GO:0006953 9.33 SERPINA1 INS F2
5 response to sucrose GO:0009744 9.26 PNPLA3 ADIPOQ
6 nitrogen compound metabolic process GO:0006807 9.13 SEC63 PRKCSH PKD1
7 cellular protein metabolic process GO:0044267 9.1 SERPINA1 PRKCSH INS F2 ALB AFP

Sources for Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....